OR (95 % CI) for obesity | p value | p for interactiona | B (95 % CI)b | p value | p for interactionc | ||
---|---|---|---|---|---|---|---|
PPARG2 (rs1801282) | |||||||
Pro12Pro | 1 (ref) | 0 (ref) | |||||
Ala12 | 1.66 (1.01–2.74) | 0.045 | 0.40 (−0.13–0.90) | 0.139 | |||
FTO (rs9939609) | |||||||
TT | 1 (ref) | 0 (ref) | |||||
TA/AA | 1.03 (0.66–1.60) | 0.892 | 0.33 (−0.08–0.74) | 0.112 | |||
Genotype | |||||||
FTO e | PPARG2 e | ||||||
− | − | 1 (ref) | 0 (ref) | ||||
− | + | 1.92 (0.86–4.27) | 0.111 | 0.46 (−0.36–1.30) | 0.287 | ||
+ | − | 1.10 (0.66–1.84) | 0.704 | 0.34 (−0.11–0.79) | 0.135 | ||
+ | + | 1.71 (0.84–3.48) | 0.138 | 0.79 (0.08–1.50) | 0.030 | ||
High CHO intake (>246 g/day) | model 1/model 2 | ||||||
PPARG2 (rs1801282) | 0.046/0.030 | 0.260 | |||||
Pro12Pro | 1 (ref) | 0 (ref) | |||||
Ala12 | 2.67 (1.30–5.46) | 0.007d | 0.49 (−0.21–1.20) | 0.169 | |||
FTO (rs9939609) | 0.609/0.449 | 0.739 | |||||
TT | 1 (ref) | 0 (ref) | |||||
TA/AA | 1.15 (0.57–2.31) | 0.697 | 0.46 (−0.11–1.03) | 0.111 | |||
Genotype | |||||||
FTO e | PPARG2 e | 0.814/0.844 | 0.973 | ||||
− | − | 1 (ref) | 0 (ref) | ||||
− | + | 1.92 (0.79–6.76) | 0.312 | 0.28 (−0.03–1.43) | 0.639 | ||
+ | − | 1.04 (0.60–2.41) | 0.924 | 0.41 (−0.22–1.03) | 0.204 | ||
+ | + | 3.26 (1.19–8.89) | 0.021 | 1.07 (0.10–2.03) | 0.031 | ||
Low physical activity practice (< 18.6 METs-h/week) | model 3/model 4 | ||||||
PPARG2 (rs1801282) | 0.266/0.243 | 0.741 | |||||
Pro12Pro | 1 (ref) | 0 (ref) | |||||
Ala12 | 2.14 (1.13–4.05) | 0.020 | 0.93 (0.16–1.69) | 0.017d | |||
FTO (rs9939609) | 0.366/0.152 | 0.417 | |||||
TT | 1 (ref) | 0 (ref) | |||||
TA/AA | 1.14 (0.64–2.06) | 0.652 | 0.56 (−0.05–1.16) | 0.070 | |||
Genotype | |||||||
FTO e | PPARG2 e | 0.346/0.230 | 0.360 | ||||
− | − | 1 (ref) | 0 (ref) | ||||
− | + | 2.31 (0.79–6.76) | 0.125 | 0.63 (−0.65–1.90) | 0.334 | ||
+ | − | 1.21 (0.60–2.41) | 0.594 | 0.48 (−0.18–1.14) | 0.156 | ||
+ | + | 2.51 (1.01–6.23) | 0.047 | 1.67 (0.63–2.71) | 0.002d |